Infertility Evaluation: ASRM/AUA Workup, Semen Analysis, and Treatment Cascade

Reproductive Endocrinology · Guideline

Infertility Evaluation: ASRM/AUA Workup, Semen Analysis, and Treatment Cascade

A practical, evidence-based framework for the basic infertility evaluation — when to start the workup, how to interpret semen analysis under WHO 2021 reference values, ovarian reserve testing, tubal assessment, and the stepwise progression from ovulation induction through IUI to assisted reproduction.

📅 Updated: July 2026 ✍️ Author: gomdori, MD ⏱️ Reading time: 18 min 🔬 ASRM · ESHRE · WHO 2021

Executive Summary

Infertility — failure to conceive after 12 months of unprotected, well-timed intercourse (or 6 months if the female partner is ≥35 years) — affects approximately one in seven heterosexual couples and warrants a coordinated bilateral evaluation rather than a stepwise gendered referral. The basic workup, completed in two to three menstrual cycles, must include semen analysis (the single highest-yield first test, abnormal in 30–40% of cases), confirmation of ovulation, ovarian reserve assessment with antimüllerian hormone (AMH) and antral follicle count (AFC), and tubal patency by hysterosalpingography (HSG). Causes distribute as male factor 30–40%, ovulatory dysfunction 25–30%, tubal/peritoneal disease 25–35%, and unexplained infertility 10–15%, with significant overlap. Treatment escalates rationally: lifestyle modification, ovulation induction with letrozole 2.5–7.5 mg or clomiphene citrate 50–150 mg on cycle days 3–7, intrauterine insemination, and finally in vitro fertilization with or without intracytoplasmic sperm injection. Age is the dominant prognostic variable: live-birth rate per IVF cycle drops from ~40% under 35 to ~7% over 42, and any evaluation must place the female partner’s age at the center of counseling.

1 in 7
Couples affected
30–40%
Male factor contribution
85%
Conceive within 12 months
~7%
IVF live-birth/cycle ≥42 yr

1 · Definitions, Epidemiology & When to Refer

The American Society for Reproductive Medicine (ASRM) and American Urological Association (AUA) jointly define infertility as the failure to achieve a clinical pregnancy after twelve months or more of regular, unprotected intercourse. The threshold collapses to six months when the female partner is ≥35 years, and immediate evaluation is warranted when she is ≥40, when there is known anovulation (e.g., PCOS, hypothalamic amenorrhea), prior pelvic surgery, endometriosis, exposure to gonadotoxic chemotherapy/radiation, or a male partner with known andrological disease. The evaluation framework deliberately treats the couple as the unit of care: roughly one-third of cases trace to male factor, one-third to female factor, and one-third to combined or unexplained etiology, so a unilateral workup is both inefficient and inequitable.

When to begin the evaluation

Female ageTrigger for evaluationNotes
< 35 years≥ 12 months of failed conceptionStandard baseline; counsel on cycle tracking first
35–39 years≥ 6 months of failed conceptionInitiate workup in parallel with continued attempts
≥ 40 yearsImmediate (do not wait)Counsel on AMH-driven IVF window; oocyte cryo if delaying
Any age + red flagImmediateAnovulation, prior chemo/radiation, endometriosis, PID, surgery, partner azoospermia

Etiology distribution (overlapping categories)

  • Male factor: 30–40% — semen abnormalities, varicocele, ejaculatory dysfunction, obstructive/non-obstructive azoospermia.
  • Ovulatory dysfunction: 25–30% — polycystic ovary syndrome (most common), hypothalamic amenorrhea, hyperprolactinemia, thyroid disease, premature ovarian insufficiency.
  • Tubal/peritoneal: 25–35% — chlamydia/gonorrhea sequelae, endometriosis, prior pelvic surgery, hydrosalpinx.
  • Uterine: 5–10% — submucous fibroid, polyp, intrauterine adhesions (Asherman), congenital müllerian anomaly.
  • Unexplained: 10–15% — full standard workup negative.
ℹ️
Fecundability anchorAmong normally fertile couples in their twenties, the cycle-by-cycle probability of conception is roughly 20–25%, cumulative ~85% at 12 months and ~95% at 24 months. Below those benchmarks, evaluation is appropriate even before the formal time threshold if the patient and clinician agree.

2 · Female Workup: Ovulation, Ovarian Reserve, Anatomy

The female evaluation answers three questions in sequence: Is she ovulating? How much oocyte reserve is left? Are the tubes and uterine cavity normal? Each pillar carries a preferred test and a fallback, and the panel is generally completed within two menstrual cycles before therapeutic decisions are made.

Pillar 1 — Ovulation confirmation

  • History first. Cycles 24–35 days with reliable molimina (mittelschmerz, premenstrual breast tenderness) are 95% predictive of ovulation; oligomenorrhea (>35 d) or amenorrhea is presumptive anovulation.
  • Mid-luteal serum progesterone drawn ~7 days before expected menses (cycle day 21 in a 28-day cycle): ≥ 3 ng/mL confirms ovulation; ≥ 10 ng/mL suggests adequate luteal phase.
  • Urinary LH kits identify the LH surge ~24–36 hours before ovulation; useful for cycle timing but a positive surge alone is not proof of ovulation.
  • Anovulation workup: TSH, prolactin, FSH/LH/estradiol on cycle day 3, total testosterone and DHEA-S if hyperandrogenism, 17-OH progesterone if congenital adrenal hyperplasia suspected.

Pillar 2 — Ovarian reserve testing

Ovarian reserve does not predict natural fecundability in young women, but it is indispensable for IVF dose planning, counseling about reproductive lifespan, and identifying premature ovarian insufficiency. The contemporary panel relies on AMH and AFC; day-3 FSH is now an adjunct.

TestMethodReassuringDiminished reserve
AMHSerum, any cycle day1.0–4.0 ng/mL< 1.0 ng/mL (very low < 0.5)
AFCTransvaginal US, early follicular10–20 follicles (both ovaries)< 5–7 follicles total
Day-3 FSHSerum on cycle day 2–4< 10 mIU/mL> 10 mIU/mL (severely > 20)
Day-3 estradiolPaired with FSH< 80 pg/mL> 80 pg/mL (may falsely suppress FSH)

Pillar 3 — Tubal & uterine assessment

  • Hysterosalpingography (HSG) — first-line. Performed cycle days 5–10 (post-menstrual, pre-ovulatory). Sensitivity for tubal occlusion ~65%, specificity ~85%; oil-soluble contrast may also confer a modest fertility-enhancing effect (H2Oil trial).
  • Saline infusion sonohysterography (SIS) for cavity assessment when HSG suggests filling defect or polyp/fibroid suspected.
  • Hysteroscopy when SIS or HSG abnormal — gold standard for cavity, allows simultaneous resection.
  • Diagnostic laparoscopy reserved for suspected endometriosis or distal tubal disease; not first-line because morbidity exceeds yield in the absence of pelvic pain or prior PID.
⚠️
HSG safety pearlsPre-procedure NSAID 30–60 minutes before; offer doxycycline 100 mg PO BID × 5 d if history of PID or hydrosalpinx; never perform during active vaginal bleeding or suspected pregnancy (urine βhCG day-of).
Infertility Evaluation — Comparison Comparison table: Infertility Evaluation — Comparison Male factor (40%) Ovulatory (15%) Tubal (15%) Uterine (5%) Unexplained (10%) Description Semen analysis: count, motility, morphology; varicocele, hormonal PCOS most common; hyperprolactinemia, thyroid, hypothalamic PID, endometriosis, prior surgery; HSG diagnostic Fibroids (submucosal), polyps, Asherman; sonohysterography Normal workup; empiric treatment ladder
Infertility Evaluation — Comparison

3 · Male Workup: WHO 2021 Semen Analysis

Semen analysis is the cornerstone male test and should be obtained early — ideally before any female testing escalates beyond cycle-day labs. The WHO 6th edition (2021) lower reference limits replace the previous WHO 2010 thresholds and represent the lowest 5th centile of fertile men whose partner conceived within 12 months. Two abnormal samples spaced 1–3 months apart are required to confirm an abnormality, since intra-individual variability is substantial.

ParameterWHO 2021 lower reference (5th centile)Term for abnormality
Semen volume≥ 1.4 mLHypospermia
Sperm concentration≥ 16 million/mLOligozoospermia
Total sperm number≥ 39 million/ejaculateOligozoospermia (total)
Total motility (PR + NP)≥ 42%Asthenozoospermia
Progressive motility≥ 30%Asthenozoospermia (PR)
Normal morphology (strict)≥ 4%Teratozoospermia
Vitality (live)≥ 54%Necrozoospermia
AzoospermiaNo sperm in centrifuged pelletEndocrine + genetic workup

Specimen collection rules

  • Abstinence 2–7 days (deviating either way changes concentration).
  • Collected by masturbation into a sterile, non-spermicidal container; whole ejaculate must be captured.
  • Delivered to lab within 60 minutes, kept at body temperature.
  • If clinic collection impossible, special non-toxic collection condoms exist (no latex).

Workup of abnormal semen

For severe oligospermia (< 5 million/mL) or azoospermia, escalate immediately:

  • Hormonal panel — total testosterone (8–10 a.m.), FSH, LH, prolactin, estradiol, TSH. Elevated FSH with low testosterone → primary testicular failure; low/normal FSH with low testosterone → secondary (hypogonadotropic).
  • Genetic testing in azoospermia or severe oligospermia — karyotype (Klinefelter 47,XXY found in 5–10%), Y-chromosome microdeletion (AZFa/b/c), CFTR mutation (congenital absence of vas deferens).
  • Scrotal ultrasound for varicocele, mass, ductal abnormality.
  • Post-ejaculate urinalysis if low volume / azoospermia — sperm in urine indicates retrograde ejaculation.
  • Urology referral for varicocelectomy candidacy, microsurgical TESE in non-obstructive azoospermia, or vasal reconstruction.
Standard infertility evaluation cascade Coupled bilateral evaluation showing semen analysis, ovulation confirmation, ovarian reserve, and tubal assessment converging into treatment cascade from OI to IVF. Infertile Couple ≥12 mo (or ≥6 if ≥35 yr) Female Partner Male Partner Ovulation Mid-luteal P4 Reserve AMH + AFC Tubal HSG Semen Analysis (WHO 2021) ×2 if abnormal · vol ≥1.4 · conc ≥16M · mot ≥42% · morph ≥4% Diagnosis & Counseling Step 1 · OI ± TI Letrozole 2.5–7.5 mg Clomiphene 50–150 mg Step 2 · IUI 3–6 cycles ~10–15% per cycle Step 3 · IVF ± ICSI ~40% <35 yr · ~7% ≥42 yr PGT-A optional Direct-to-IVF: bilateral tubal occlusion · severe male factor · ≥40 yr · low reserve PGT-M for known monogenic disease · PGT-SR for translocation carriers
Figure 1. Coupled evaluation cascade. Both partners are tested simultaneously; results converge into a single counseling visit before the stepwise treatment ladder is initiated.
Infertility Evaluation — Procedure Steps Surgical stepper: Infertility Evaluation — Procedure Steps Infertility Evaluation — Procedure Steps 1 Initial workup Semen analysis (2 samples); CD3 FSH, LH, E2; CD21 progesterone for ovulation; HSG; TSH, prolactin 2 Ovulation induction Letrozole 2.5-7.5mg cycle days 3-7 (preferred PCOS) OR clomiphene 50-150mg; monitor with US 3 Intrauterine insemination IUI with ovulation induction × 3-6 cycles; for mild male factor or unexplained 4 In vitro fertilization IVF for: tubal disease, severe male factor, advanced age, IUI failure, endometriosis 5 Donor gametes Donor sperm (severe oligospermia/azoospermia); donor egg (POI, advanced age) 6 Lifestyle + adjunct Weight optimization (BMI 18.5-30); smoking/alcohol cessation; folate; coenzyme Q10
Infertility Evaluation — Procedure Steps

4 · Treatment Cascade: OI → IUI → IVF

The treatment ladder is anchored on female age, ovarian reserve, and the specific diagnosis. For ovulatory dysfunction with patent tubes and a normal semen analysis, ovulation induction is first-line; for unexplained infertility, the AMIGOS/FORTT/FASTT trials support up to three IUI cycles before escalation; for tubal disease, severe male factor, or age ≥40 with low reserve, direct-to-IVF saves time and money.

Ovulation induction — letrozole vs clomiphene

DrugMechanismDoseNotes
Letrozole (preferred for PCOS)Aromatase inhibitor → ↓ estrogen → ↑ FSH2.5 mg PO daily × 5 d, cycle days 3–7; titrate to 5–7.5 mgHigher live-birth than clomiphene in PCOS (PPCOS-II); off-label but ASRM/ACOG endorsed
Clomiphene citrateSelective estrogen receptor modulator (hypothalamus)50 mg PO daily × 5 d, cycle days 3–7 (or 5–9); up to 150 mgAnti-estrogenic effects on cervical mucus and endometrium; 6-cycle maximum
Metformin (PCOS adjunct)Insulin sensitizer500 mg PO TID titrate to 1500–2000 mg/dayUse if BMI > 30 or insulin resistance; not standalone fertility drug

Cycle monitoring includes mid-cycle transvaginal ultrasound to confirm a dominant follicle (~18–24 mm) and an LH surge or hCG trigger. Progesterone is checked 7 days after ovulation. Move to next step after 3–6 ovulatory cycles without conception.

Gonadotropins & intrauterine insemination

IUI bypasses the cervix by depositing washed, motile sperm directly into the uterine cavity timed to ovulation, raising per-cycle pregnancy rates to ~10–15%. It is most effective when paired with ovulation induction (clomiphene/letrozole or low-dose injectable FSH such as menotropins 75 IU SC daily with serial follicular monitoring). Three IUI cycles are typically attempted before IVF. Risks include multiple gestation (~10%) and ovarian hyperstimulation syndrome with gonadotropins.

  • Indications: mild-moderate male factor (post-wash motile count ≥ 5–10 million), unexplained infertility, cervical factor, sexual dysfunction, single individuals or same-sex female couples using donor sperm.
  • Contraindications: bilateral tubal occlusion, severe male factor (post-wash < 5 million), advanced maternal age with low reserve.
  • Trigger: recombinant hCG 250 mcg SC or urinary hCG 5,000–10,000 IU SC when lead follicle ≥ 18 mm; insemination 24–36 h later.

In vitro fertilization, ICSI, and PGT

IVF involves controlled ovarian hyperstimulation (typically antagonist protocol with recombinant FSH 150–300 IU SC daily ± low-dose hMG, GnRH antagonist cetrorelix 0.25 mg SC daily from day 5–6, GnRH agonist trigger or hCG trigger), transvaginal oocyte retrieval 34–36 hours later, fertilization in the lab, and embryo transfer (fresh or frozen). Per-cycle live-birth rates depend overwhelmingly on female age:

Female ageIVF live-birth/cycle (US SART data)Multiple gestation (single ET)
< 35~40–45%~1.5%
35–37~30–35%~1.5%
38–40~20–25%~1%
41–42~10–15%< 1%
> 42~5–7%< 1%
Donor egg (any age)~50%~1.5%

ICSI indications

  • Severe male factor (low concentration, motility, or morphology)
  • Surgically retrieved sperm (TESA, TESE, MESA)
  • Prior IVF cycle with low/zero fertilization
  • Need for PGT (single sperm injection prevents extraneous DNA contamination)

Preimplantation genetic testing

  • PGT-A — aneuploidy screening; useful in advanced maternal age, recurrent pregnancy loss, recurrent IVF failure (STAR trial showed mixed benefit; not routine).
  • PGT-M — single-gene disorders (CF, sickle cell, Tay-Sachs, BRCA carriers electing prevention).
  • PGT-SR — structural rearrangements (balanced translocation carriers).
🏥
When to refer to reproductive endocrinology & infertility (REI)Female age ≥ 40 at initial visit · failure of 3 ovulation-induction cycles · azoospermia or severe oligospermia · bilateral tubal occlusion or hydrosalpinx (laparoscopic salpingectomy improves IVF outcome) · recurrent pregnancy loss ≥ 2 · same-sex female couples requiring donor sperm · oncofertility (chemo/radiation pending) for urgent oocyte/embryo cryopreservation.

5 · Special Populations & Counseling

Standard pathways require modification for several patient groups; the table below distills the most common adjustments.

PopulationWorkup adjustmentTreatment adjustment
PCOSAdd OGTT, fasting lipid, 17-OH progesterone if hyperandrogenismLetrozole first-line; metformin if BMI > 30; weight loss 5–10% restores ovulation in ~40%
Hypothalamic amenorrheaLow FSH/LH/E2; check eating disorder, exercise stressRestore caloric intake / reduce exercise; pulsatile GnRH or gonadotropins for OI; clomiphene/letrozole ineffective (no functional axis)
Diminished ovarian reserveAMH < 1.0, AFC < 7, FSH > 10Skip OI/IUI ladder; proceed directly to IVF; counsel donor egg early; DHEA 25 mg PO TID × 12 wk pre-IVF (controversial)
EndometriosisCA-125 elevated > 35 in 50%; pelvic US for endometrioma; laparoscopy for definitive DxStage I/II — surgical ablation modestly improves; Stage III/IV — proceed to IVF; cyst > 4 cm consider cystectomy first
HydrosalpinxHSG or US shows dilated tubeLaparoscopic salpingectomy or proximal occlusion before IVF (doubles live-birth rate)
Recurrent pregnancy loss (≥ 2)Karyotype both partners, antiphospholipid Ab, TSH, prolactin, hysteroscopyTreat underlying cause; PGT-A if structural rearrangement; aspirin + LMWH for confirmed APS
Oncofertility (pre-chemo)Urgent same-day REI; AMH baselineRandom-start ovarian stim with letrozole co-administration (BRCA/breast Ca); oocyte or embryo cryopreservation; ovarian tissue cryo if < 2 wk
Same-sex female couples / single womenStandard female workup; donor sperm screeningIUI with donor sperm; reciprocal IVF (one partner provides oocyte, other carries) on request
Klinefelter (47,XXY)Karyotype confirms; check FSH, T, semen analysis (usually azoospermia)Microsurgical TESE — sperm retrieval ~50%; ICSI; testosterone replacement only after fertility plan finalized

Pre-conception counseling — checklist

  • Folic acid 400–800 mcg PO daily (4 mg if prior NTD, on antiepileptic, or diabetic).
  • Smoking cessation, alcohol < 1 drink/day, recreational drug discontinuation.
  • BMI optimization 19–30 (every 5-unit increase above 25 reduces fecundability ~5%).
  • Vaccinations updated: MMR, varicella, Tdap, influenza, COVID-19.
  • Screen for diabetes, thyroid disease, hypertension, anemia, hepatitis B/C, HIV.
  • Genetic carrier screening (CF, SMA, hemoglobinopathies, ethnicity-specific panel).
  • Optimize chronic medications (avoid teratogens — ACE-I, statins, isotretinoin, valproate; switch SSRI to safer agent if needed).

6 · Pearls, Pitfalls & FAQ

✓ Pearl 1 — Couple, not the woman

Always order semen analysis before HSG. Male factor accounts for 30–40% of cases, the test costs less than HSG, carries no procedural risk, and can spare an unnecessary tubal study. The reverse order is one of the most common workup errors in primary care.

✗ Pitfall 1 — “Just keep trying”

Watchful waiting beyond the formal ASRM/AUA threshold is harmful, not benign — for a 38-year-old woman, every six months of delayed evaluation costs roughly 5% absolute live-birth chance per IVF cycle. Initiate workup at six months if she is ≥35; immediately if ≥40 or red flags present.

✓ Pearl 2 — Letrozole over clomiphene in PCOS

The PPCOS-II trial showed letrozole produced 27.5% live-birth vs 19.1% with clomiphene in PCOS women (NEJM 2014). Letrozole avoids clomiphene’s anti-estrogenic endometrial thinning and cervical mucus effects. It remains off-label for ovulation induction but is endorsed by ASRM as first-line for PCOS.

✗ Pitfall 2 — Repeating semen with no abstinence control

Specimens collected with < 2 days or > 7 days of abstinence have artificially low concentration or volume. A semen analysis with uncontrolled abstinence or single-sample abnormality should not drive a referral; obtain two specimens 1–3 months apart with documented 2–7 day abstinence before labeling male factor.

✓ Pearl 3 — Treat hydrosalpinx before IVF

A dilated, fluid-filled tube reduces IVF live-birth by ~50% via reflux of cytotoxic fluid into the uterine cavity. Laparoscopic salpingectomy (preferred) or proximal tubal occlusion before embryo transfer roughly doubles live-birth rate (Cochrane 2010). Counsel and refer aggressively.

✗ Pitfall 3 — Treating “low AMH” in young women with watchful waiting

AMH does not predict natural fecundability in women < 35 — it predicts ovarian response to IVF stimulation. A young woman with low AMH and otherwise normal workup can still conceive naturally; however, urgency for evaluation increases because reproductive runway is shorter than chronologic age suggests.

Frequently asked questions

When should a couple begin an infertility evaluation?
If the female partner is younger than 35, evaluation is indicated after 12 months of regular, unprotected intercourse without conception. The threshold drops to 6 months if she is 35–39, and to immediate evaluation if she is 40 or older. Earlier evaluation is also appropriate for known anovulation, prior pelvic surgery, endometriosis, history of pelvic infection, gonadotoxic chemotherapy or radiation, or known andrological disease in the male partner.
Why is semen analysis ordered before tubal testing?
Male factor causes 30 to 40 percent of infertility, semen analysis is non-invasive and inexpensive, and a definitively abnormal result can spare the female partner a hysterosalpingography. Ordering HSG before semen analysis is one of the most common workup errors and exposes the patient to procedural risk and radiation that may turn out to be unnecessary.
What does AMH tell us, and what does it not tell us?
Antimüllerian hormone reflects the size of the resting follicle pool and predicts ovarian response to controlled stimulation in IVF. It does not predict natural fecundability in young women with otherwise normal workup, and a low AMH alone is not a diagnosis of infertility. Its main value is for IVF dose planning, identification of premature ovarian insufficiency, and counseling about the reproductive lifespan.
Letrozole or clomiphene — which is first-line for ovulation induction?
For polycystic ovary syndrome, letrozole 2.5 mg orally daily on cycle days 3 through 7 is first-line based on the PPCOS-II trial, which demonstrated higher live-birth rates than clomiphene. For non-PCOS ovulatory dysfunction or unexplained infertility, either agent is acceptable. Letrozole avoids the anti-estrogenic endometrial and cervical mucus effects of clomiphene but remains off-label for ovulation induction.
How many IUI cycles before moving to IVF?
For unexplained infertility or mild male factor, three IUI cycles paired with ovulation induction are typically attempted before escalation to IVF, based on the AMIGOS and FASTT trials. Direct-to-IVF without an IUI trial is appropriate for bilateral tubal occlusion, severe male factor with post-wash motile count below 5 million, and women aged 40 or older with diminished ovarian reserve, where time and cost favor proceeding immediately.

gomdori medical · Evidence-based clinical reference · Author: gomdori, MD

This article is for educational purposes only and is not a substitute for individualized medical advice from a licensed clinician.

Practice Insights: Lessons from a Decade in a Mixed PCP–Reproductive-Endocrine Practice

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Whether to work a couple up now or wait another six months is the decision that shapes infertility care, because the workup is mostly about not wasting the patient’s ovarian reserve clock and not misinterpreting biomarkers in either direction. In experienced practice the patterns experienced clinicians track most carefully are the chronic referral delay in women over 35, the AMH overinterpretation that distorts couples’ expectations, the WHO 2021 semen-analysis cutoff confusion in primary care, and the temptation to layer three to six cycles of empiric ovulation induction on women who actually ovulate normally.

Infertility Evaluation: Referral Timing, AMH Interpretation, WHO 2021 Semen Thresholds, Treatment Cascade Four-panel matrix showing age-based referral timing, AMH interpretation grid, WHO 2021 semen analysis thresholds versus 2010, and treatment cascade by diagnostic phenotype. Infertility: Four Bedside Decisions That Set the Trajectory ① Age-Stratified Referral Timing Female age Trying time before workup < 35 years 12 months 35–39 years 6 months ≥ 40 years Immediate (no waiting) Known risk (PCOS, endometriosis, prior chemo) Immediate Refer EARLY — workup is the work; cycle delay is the cost ② AMH: What It Predicts (and Doesn’t) AMH DOES predict: ▸ Response to ovarian stimulation (oocyte yield) ▸ Time to menopause (population level) ▸ Cycle-cancellation risk in IVF AMH does NOT predict: ▸ Chance of natural conception this cycle ▸ Individual age-of-menopause (huge CIs) ▸ Whether to delay childbearing safely Interpret as “ovarian reserve for stimulation,” never as a “fertility number” to patients ③ Semen Analysis: WHO 2021 vs 2010 Parameter WHO 2010 WHO 2021 Volume (mL) ≥ 1.5 ≥ 1.4 Concentration (M/mL) ≥ 15 ≥ 16 Total count (M) ≥ 39 ≥ 39 Total motility (%) ≥ 40 ≥ 42 Progressive motility (%) ≥ 32 ≥ 30 Normal morphology (%) ≥ 4 ≥ 4 Confirm abnormal with 2nd analysis ≥ 3 weeks apart 3-day abstinence before sample ④ Treatment Cascade by Phenotype Diagnosis First-line PCOS / anovulation Letrozole 2.5 mg × 5 d Hypothalamic anovulation Pulsatile GnRH or gonadotropins Mild male factor IUI ± OI × 3 cycles Severe male factor ICSI (skip IUI) Tubal disease IVF (skip IUI) Unexplained, female < 38 IUI + OI × 3 → IVF Unexplained, female ≥ 38 Direct to IVF Don’t layer OI on normo-ovulatory unexplained — wastes time

1. Refer at Six Months for Women 35–39, Immediately for ≥ 40

The pattern experienced clinicians see most often in primary care is a 38-year-old patient politely advised to “try for another six months” and then “another six months” before any workup is ordered. In experienced practice that conversation costs the couple roughly 15% of remaining oocyte reserve per year, and the resulting IVF cycle outcome is materially worse than it would have been twelve months earlier. Seasoned clinicians now refer any woman between 35 and 39 after exactly six months of unprotected intercourse without conception, and any woman 40 or older at presentation regardless of trying duration. The patient may decline the workup — that is their decision, not the clinician’s — but the conversation needs to happen.

2. AMH Is Not a “Fertility Test”

One of the most damaging miscommunications experienced practitioners encounter is the patient who arrives clutching a direct-to-consumer AMH result and tells them they are “still very fertile” or “running out of time” based on that number alone. In practice they now reframe AMH explicitly: it predicts how many eggs will likely be recovered during ovarian stimulation, and it loosely correlates with the timing of menopause at a population level. It does not predict whether they will conceive this cycle, this year, or whether they can safely defer pregnancy. Experienced clinicians would rather have an uncomfortable five-minute reframe than have the patient make childbearing decisions on a misread biomarker.

3. WHO 2021 Reclassified a Lot of “Abnormal” Semen as Normal

The semen analyses seasoned clinicians see referred to them are still being interpreted against WHO 2010 thresholds half the time, and clinicians have learned to always recheck against WHO 2021 before believing a “male factor” label. The biggest shifts in practice are progressive motility dropping from 32% to 30% and total motility rising from 40% to 42%, with the morphology cutoff at 4% essentially unchanged but increasingly de-emphasized clinically. Any genuinely abnormal result requires a second sample at least three weeks later with a documented three-day abstinence period — single-sample diagnoses are not actionable in experienced hands.

4. Empiric OI Is for Anovulators, Not Everyone

The single most common time-wasting mistake experienced practitioners see in community-based fertility care is empiric letrozole or clomiphene given to women who are ovulating normally. The evidence is consistent: in normo-ovulatory unexplained infertility, three to six cycles of oral ovulation induction produce minimal improvement in live-birth rate compared with the same time spent on expectant management or moving to IVF. In experienced practice clinicians reserve letrozole for true anovulation (PCOS, oligomenorrhea with absent LH surge on monitoring), and experienced clinicians move normo-ovulatory unexplained infertility directly to a structured IUI-plus-stimulation cascade with a firm three-cycle ceiling before IVF.

Illustrative Scenario

A patient in her late thirties presented to primary care after 14 months of unprotected intercourse without conception. She had regular menses with documented mid-luteal progesterone of 12 ng/mL on a prior cycle, no risk factors for tubal disease, and a partner with a normal-appearing semen analysis interpreted under the older 2010 thresholds. A consumer-tested AMH was returned at 1.1 ng/mL, and she had been told by another clinician that this meant she was “in perimenopause” and “should consider donor eggs.”

The treating clinicians reframed the AMH explicitly as a stimulation-response marker rather than a fertility verdict. Workup proceeded with day-3 FSH/estradiol (FSH 9.8, estradiol 48), antral follicle count of 7 (low-normal for age), thyroid and prolactin normal, hysterosalpingogram with patent tubes. Repeat semen analysis interpreted under WHO 2021 was normal in all parameters with a borderline morphology of 3% that no longer carries the prognostic weight it once did. The couple was counseled as normo-ovulatory unexplained infertility with low-normal ovarian reserve; rather than three to six cycles of empiric letrozole, the treating clinicians moved directly to three cycles of IUI with letrozole stimulation, and to IVF if needed. Pregnancy occurred on the second IUI cycle.

Takeaway: A low AMH in a normo-ovulatory patient is not a verdict; it is a stimulation-yield prediction. Reframe before the patient builds a life decision on it.

Standing Protocol Adjustments

  1. Initiate workup at six months for women 35–39, and immediately for women 40 and older, regardless of patient preference for more “natural” trying time; document the conversation and let the patient decline the workup if they choose.
  2. Reframe AMH at every encounter as a marker of stimulation response and rough menopause-timing at the population level, not as a fertility verdict; never deliver an AMH number without context.
  3. Interpret every semen analysis against WHO 2021 thresholds and require a second confirmatory sample ≥ 3 weeks apart with documented 2–7 day abstinence; never act on a single abnormal result.
  4. Reserve letrozole and clomiphene for true anovulation; move normo-ovulatory unexplained infertility directly to a structured three-cycle IUI plus stimulation cascade, then to IVF, rather than layering empiric oral OI.

Leave a Reply

Your email address will not be published. Required fields are marked *